Ravenna

• A PROJECT FOR TWO MULTICENTRE, PROSPECTIVE OPEN LABEL RANDOMIZED CLINICAL STUDIES TO EVALUATE THE EFFECT OF TARGETED THERAPY BASED ON KIDNEY … Pending
  2024-517861-18-00 5 Idiopathic IgA nephropathy (IgAN)
• Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant treatment of HER2 positive early high-risk and locally advanced br … Pending
  2024-518026-32-00 5 Invasive Breast Cancer
• Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET deregulation Pending
  2024-518386-95-02 4 Non small-cell lung cancer
• The effect of phoSPHocreatine on mEdical emergency team (met) tREated patients: a randomized clinical trial protocol – SPHERE Pending
  2024-518474-14-00 5 respiratory arrest
• Clinical trial investigating the efficacy of gilteritinib and chemotherapy treatment in patients with Acute myeloid leukemia Pending
  2024-518617-25-00 4 newly diagnosed non-M3 FLT3-positive acute myeloid leukemia
• A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy with Standard-of-Care Combination Regimens … Pending
  2024-519504-27-00 5 Relapsed Refractory Multiple Myeloma
• A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults with Type 2 D … Pending
  2024-520068-32-00 6 Type 2 diabetes
• Personalized antibiotic TREATment for febrile Urinary Tract Infections in children (TREAT-UTI study): multicenter randomized controlled tria … Pending
  2025-520622-38-00 5 Urinary Tract Infections
• A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tum … Pending
  2025-521209-42-00 6 advanced colorectal cancer with wild-type RAS and right primary tumour
• Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants With Ad … Pending
  2025-521221-32-00 5 Advanced or Metastatic Non-Small Cell Lung Cancer
• Hyperprogression upon cemiplimab alone or with chemotherapy in PD-L1 ≥ 50% NSCLC: a biomarker guided phase 2 trial – HYPERBOLIC study Pending
  2025-521583-35-00 4 non-small cell lung cancer (NSCLC)
• IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after … Pending
  2025-521908-22-00 10 EGFR-mutated Non-small Cell Lung Cancer
• Phase 3 Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Platinum Resistant Ovarian Cancer With Cyclin E1 Overexpression Pending
  2025-522748-42-00 5 Ovarian cancer
• A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell L … Pending
  2025-522818-23-00 5 Small Cell Lung Cancer (SCLC)
• A Study to Learn about the Study Medicine called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers Pending
  2025-523526-40-00 9 Advanced Solid Tumors
• A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treat … Pending
  2025-523735-19-00 5 Metastatic Microsatellite Stable Colorectal Cancer
• Paclitaxel plus ramucirumab and tislelizumab as switch maintenance versus continuation of chemotherapy and tislelizumab in patients with adv … Pending
  2025-524048-36-00 5 Advanced HER2-negative and PD-L1 positive gastroesophageal adenocarcin
• A Phase II, Open-Label Randomized Study of Intravenous Tambiciclib in Combination with the Standard of care Venetoclax and Azacitidine in Pa … Pending
  2025-524308-31-00 4 Acute myeloid leukemia
• A Research Study Testing New Cancer Medicines Used Alone or Together to Treat Solid Tumors Pending
  2025-524623-50-00 9 Solid Tumors
• A Study of Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC Recruiting
  2025-523576-23-00 5 2026-06-12 Unresectable Stage III non-small cell lung cancer without progression
• MAVRiC studies 2L treatment with AV in patients with CLL/SLL who have relapsed after a course of BTKi + BCL2i combination, with and without … Recruiting
  2024-518858-17-00 4 2026-05-22 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
• A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants with Platinum-Resistant (Part A) and Platinum-Sensitive (Part B … Recruiting
  2025-522255-25-00 5 2026-05-18 Fallopian Tube Neoplasms
• A Global Study Testing the New Drug Olverembatinib combined with chemotherapy for Patients with Newly Diagnosed Philadelphia Chromosome-Pos … Recruiting
  2024-511496-14-00 5 2026-05-14 Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic L
• Pharmacological optimization in prevention in Heart Failure: A Sex-gap? Recruiting
  2025-520660-18-00 6 2026-05-08 Heart Failure

Showing 1–24 of 233 trials